NASDAQ:PNT POINT Biopharma Global (PNT) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$12.45▼$14.2352-Week Range N/AVolume3.29 million shsAverage Volume1.44 million shsMarket Capitalization$1.33 billionP/E Ratio13.89Dividend YieldN/APrice Target$12.50 Stock AnalysisStock Analysis Get POINT Biopharma Global alerts: Email Address Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About POINT Biopharma Global Stock (NASDAQ:PNT)POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.Read More Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << PNT Stock News HeadlinesJuly 24, 2024 | markets.businessinsider.comProta Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick MachadoMay 20, 2024 | msn.comWhat's Going On With GT Biopharma Stock?September 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…April 8, 2024 | bloomberg.comInvesting in biopharma innovation: Can you stay one step ahead?January 8, 2024 | businesswire.comDomain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology CompanyDecember 27, 2023 | finance.yahoo.comLilly Completes Acquisition of POINT BiopharmaDecember 22, 2023 | markets.businessinsider.comPOINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition ProspectsDecember 22, 2023 | msn.comBrookline Capital Downgrades POINT Biopharma Global (PNT)September 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…December 22, 2023 | benzinga.comPOINT Biopharma Global Stock (NASDAQ:PNT), Guidance and ForecastDecember 18, 2023 | msn.comLilly extends tender offer for POINT Biopharma to Dec. 22December 18, 2023 | seekingalpha.comWhy POINT Biopharma Global Is At Least A Hold On Disappointing ReadoutDecember 18, 2023 | markets.businessinsider.comLantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study ResultsDecember 8, 2023 | msn.comPOINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should KnowDecember 4, 2023 | markets.businessinsider.comLilly Says Tender Offer Expiration Extended Related To POINT Biopharma AcquisitionNovember 30, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Regeneron (REGN) and Incyte (INCY)November 17, 2023 | markets.businessinsider.comHold Rating on POINT Biopharma Global: An Assessment of Acquisition Offer, Pipeline Updates, and Financial StabilityNovember 17, 2023 | finance.yahoo.comLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023See More Headlines Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PNT CUSIPN/A CIK1811764 Webwww.pointbiopharma.com Phone64-7812-2417FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$12.50 Low Stock Price Target$12.50 Consensus RatingHold Rating Score (0-4)2.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.90 Trailing P/E Ratio13.89 Forward P/E RatioN/A P/E GrowthN/ANet Income$98.29 million Net Margins39.62% Pretax Margin52.16% Return on Equity21.10% Return on Assets18.28% Debt Debt-to-Equity Ratio0.01 Current Ratio9.14 Quick Ratio9.14 Sales & Book Value Annual Sales$226.58 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow13.31 Book Value$4.68 per share Price / BookN/AMiscellaneous Outstanding Shares106,570,000Free Float89,518,000Market Cap$1.33 billion OptionableOptionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Allan Charles Silber (Age 73)Executive Chairman Comp: $1.02MDr. Joe A. McCann Ph.D. (Age 45)CEO & Director Comp: $1.06MDr. Neil E. Fleshner FRCSC (Age 59)M.D., M.PH, Chief Medical Officer & Director Comp: $318.49kMs. Jessica D. Jensen M.P.H. (Age 43)Executive Vice President of Clinical Development Comp: $816.17kMr. Bill Demers B.B.A. (Age 64)F.C.A., FCPA, CFO & Corporate Secretary Comp: $78.26kMs. Justyna Kelly M.Sc. (Age 38)Chief Operating Officer Ms. Jazz BraichSVP of People & CultureMr. Ari ShomairVP of Corporate Affairs & Chief of StaffDr. Myra Rosario Herle Ph.D.R.Ph., Executive Vice President of Regulatory AffairsDr. Matthew P. Vincent J.D.Ph.D., Senior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsESS TechNYSE:GWHMarkforgedNYSE:MKFGOwletNYSE:OWLTHims & Hers HealthNYSE:HIMSMadrigal PharmaceuticalsNASDAQ:MDGLView All Competitors PNT Stock Analysis - Frequently Asked Questions How were POINT Biopharma Global's earnings last quarter? POINT Biopharma Global Inc. (NASDAQ:PNT) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.07. The firm had revenue of $2.79 million for the quarter, compared to analysts' expectations of $8 million. POINT Biopharma Global had a net margin of 39.62% and a trailing twelve-month return on equity of 21.10%. This page (NASDAQ:PNT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share POINT Biopharma Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PNT Stock Alerts